FT009 | Future&Tech

주메뉴 바로가기 본문 바로가기

R&D

Pipeline

You can scroll left and right to view the full content.

Pipeline	Development Projects	Target diseases	Development of drug candidate	Safety test	Preclinical trials	Clinical trial - phase 1	Clinical trial - phase 2
FT005	FT005-002 (Hulk)	Chronic kidney disease
		Sarcopenia (muscle atrophy with aging)
		Muscular dystrophy
FT006	FT006-001 (Batman)	COVID prevention
FT007	FT005-002 (Hulk)	Cancer cachexia
FT007	FT005-007 (Steve)	Cancer cachexia
FT009	FT005-002 (Hulk)	Type 2 diabetes
FT011	FT005-005 (Paul)	Melanoma (skin cancer)
FT012	FT005-006 (Kyte)	Melanoma (skin cancer)

FT005-002 (Hulk) Project (Target antigen: GDF-8, myostain)

Type 2 diabetes immunotherapy

Type 2 diabetes immunotherapy - Mechanism of action, Development progress,Market size,Competitors and their products
Mechanism of action	Insulin-like growth factor (IGF) Neutralizes myostatin, which negatively regulates signal transduction pathways Maximizes insulin activitiy, promotes muscle growth, and increases muscle fiber size, unit weight, and strength Increases glucose uptake and reduces blood sugar levels
Development progress	Confirmed antibody formation and weight gain in normal mice Preparing efficacy test on disease model mice Discussing joint R&D with Gachon University GIL Medical Center
Market size	USD 161.7 billion as of 2022 Approximately KRW 218 trillion. FX: 1,350 KRW/USD
Competitors and their products	Insulin, DPP-4 inhibitor, GLP-1 Agonist, SGLT2 inhibitor Novo Nordisk, Sanofi, Merck & Co., Inc., Eli Lilly and Company, AstraZeneca

Type 2 diabetes immunotherapy commercialization plan

Technology transfer plan for muscular dystrophy immunotherapy - Prospective technology recipient, Target milestone, Total technology transfer target fee, Remarks (including terms of agreement)
Prospective technology recipient	Target milestone	Total technology transfer target fee	Remarks (including terms of agreement)
Big Pharma	Phase 1 IND approval	KRW 9 billion (1% of the market)	Royalty: 5% of revenue
Big Pharma	Phase 2 approval	KRW 1.8 trillion (2% of the market)	Royalty: 10% of revenue